May 2010:
Proof of concept trials have completed and AKL1 (aka APPA) was shown to have a significant positive effect on Osteoarthritis. These trials were contracted by AKL with a leading US research institute which is soley focused on research in inflammatory diseases. We are doing further analysis on the results and we expect this work to be completed by end 2Q / early 3Q 2010.
 
Winter 2010:
Funded by the International Primary Care Respiratory Group and sponsored by AKL Technologies, the University of East Anglia is continuing patient recruitment for the Phase II trial which is investigating the Safety and Efficacy of Oral AKL1 in Patients Diagnosed with Obstructive Lung Disease. Led by Dr Andrew Wilson, this is an extension of the DDX trial previously undertaken by Dr Mike Thomas at Aberdeen University.
 
May 2008:
The AKL4 (aka APPA) Osteoarthritis efficacy trial has completed successfully at the University of Vienna. A statistically significant, positive signal was obtained and no adverse effects were observed in the trial dogs. The trial results represent important validation of APPA’s effectiveness and a good indication of its safety. A full report is now being prepared by the University. AKL is in the process of determining the next development steps.
 
April 2008:
The MHRA has approved all of the amendments filed by Dr Mike Thomas on the AKL1 DDX extension. Key amendments approved included a substantial increase in patient recruitment and a broadening of the entry criteria. AKL is currently evaluating how best to help support this research.
 
December 2007:
Dr Mike Thomas, Asthma Fellow and Principal Investigator on the AKL1 Aberdeen DDX trial, has been given approval by the MHRA to undertake an extension to that trial, with a larger patient population.
 
June 2006:
The AKL1 double blinded placebo controlled DDX Trial Results were be presented by Dr. Mike Thomas at the International Primary Care Respiratory Group (IPCRG) meeting in Olso.
 
February 2006:
The University Aberdeen DDX Asthma trial successfully completed. Consistent treads were seen to improvements in patient-centred outcomes that favoured active treatment over placebo.
 
Please contact us for further information.